SGK3 Sustains ERα Signaling and Drives Acquired Aromatase Inhibitor Resistance Through Maintaining Endoplasmic Reticulum Homeostasis

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 2017 Feb 9

PMID 28174265

Citations 17

Authors

Yuanzhong Wang

Dujin Zhou

Sheryl Phung

Charles Warden

Rumana Rashid

Nymph Chan

Shiuan Chen

Affiliations

Soon will be listed here.

Abstract

Many estrogen receptor alpha (ERα)-positive breast cancers initially respond to aromatase inhibitors (AIs), but eventually acquire resistance. Here, we report that serum- and glucocorticoid-inducible kinase 3 (SGK3), a kinase transcriptionally regulated by ERα in breast cancer, sustains ERα signaling and drives acquired AI resistance. SGK3 is up-regulated and essential for endoplasmic reticulum (EnR) homeostasis through preserving sarcoplasmic/EnR calcium ATPase 2b (SERCA2b) function in AI-resistant cells. We have further found that EnR stress response down-regulates ERα expression through the protein kinase RNA-like EnR kinase (PERK) arm, and SGK3 retains ERα expression and signaling by preventing excessive EnR stress. Our study reveals regulation of ERα expression mediated by the EnR stress response and the feed-forward regulation between SGK3 and ERα in breast cancer. Given SGK3 inhibition reduces AI-resistant cell survival by eliciting excessive EnR stress and also depletes ERα expression/function, we propose SGK3 inhibition as a potential effective treatment of acquired AI-resistant breast cancer.

Citing Articles

SGK3 overexpression correlates with a poor prognosis in endoscopically resected superficial esophageal squamous cell neoplasia: A long-term study.

Xu N, Li L, Li H, Zhang L, Zhang N, Wang P World J Gastroenterol. 2023; 29(23):3658-3667.

PMID: 37398883 PMC: 10311610. DOI: 10.3748/wjg.v29.i23.3658.

Contributions of SGK3 to transporter-related diseases.

Liao Q, Dong Q, Zhang H, Shu H, Tu Y, Yao L Front Cell Dev Biol. 2022; 10:1007924.

PMID: 36531961 PMC: 9753149. DOI: 10.3389/fcell.2022.1007924.

AKTIP loss is enriched in ERα-positive breast cancer for tumorigenesis and confers endocrine resistance.

Ng A, Zhang S, Mak V, Zhou Y, Yuen Y, Sharma R Cell Rep. 2022; 41(11):111821.

PMID: 36516775 PMC: 9837615. DOI: 10.1016/j.celrep.2022.111821.

Huaier Induces Immunogenic Cell Death CircCLASP1/PKR/eIF2α Signaling Pathway in Triple Negative Breast Cancer.

Li C, Wang X, Chen T, Li W, Zhou X, Wang L Front Cell Dev Biol. 2022; 10:913824.

PMID: 35784473 PMC: 9243662. DOI: 10.3389/fcell.2022.913824.

Ionizing radiation downregulates estradiol synthesis via endoplasmic reticulum stress and inhibits the proliferation of estrogen receptor-positive breast cancer cells.

Yang P, Feng X, Li J, Zhang T, Sheng C, Zhang L Cell Death Dis. 2021; 12(11):1029.

PMID: 34716300 PMC: 8556230. DOI: 10.1038/s41419-021-04328-w.

References

Miller T, Balko J, Arteaga C . Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. J Clin Oncol. 2011; 29(33):4452-61. PMC: 3221526. DOI: 10.1200/JCO.2010.34.4879. View

Fujii R, Hanamura T, Suzuki T, Gohno T, Shibahara Y, Niwa T . Increased androgen receptor activity and cell proliferation in aromatase inhibitor-resistant breast carcinoma. J Steroid Biochem Mol Biol. 2014; 144 Pt B:513-22. DOI: 10.1016/j.jsbmb.2014.08.019. View

Schmid E, Bhandaru M, Nurbaeva M, Yang W, Szteyn K, Russo A . SGK3 regulates Ca(2+) entry and migration of dendritic cells. Cell Physiol Biochem. 2012; 30(6):1423-35. PMC: 6175581. DOI: 10.1159/000343330. View

Tessier M, Woodgett J . Role of the Phox homology domain and phosphorylation in activation of serum and glucocorticoid-regulated kinase-3. J Biol Chem. 2006; 281(33):23978-89. DOI: 10.1074/jbc.M604333200. View

Clarke R, Shajahan A, Wang Y, Tyson J, Riggins R, Weiner L . Endoplasmic reticulum stress, the unfolded protein response, and gene network modeling in antiestrogen resistant breast cancer. Horm Mol Biol Clin Investig. 2013; 5(1):35-44. PMC: 3734561. DOI: 10.1515/hmbci.2010.073. View

Clarke R, Cook K . Unfolding the Role of Stress Response Signaling in Endocrine Resistant Breast Cancers. Front Oncol. 2015; 5:140. PMC: 4475795. DOI: 10.3389/fonc.2015.00140. View

Martin L, Farmer I, Johnston S, Ali S, Marshall C, Dowsett M . Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation. J Biol Chem. 2003; 278(33):30458-68. DOI: 10.1074/jbc.M305226200. View

Xu J, Wan M, He Q, Bassett Jr R, Fu X, Chen A . SGK3 is associated with estrogen receptor expression in breast cancer. Breast Cancer Res Treat. 2012; 134(2):531-41. PMC: 3684450. DOI: 10.1007/s10549-012-2081-x. View

Rajapaksa G, Thomas C, Gustafsson J . Estrogen signaling and unfolded protein response in breast cancer. J Steroid Biochem Mol Biol. 2016; 163:45-50. DOI: 10.1016/j.jsbmb.2016.03.036. View

10.

Sahoo S, Shaikh S, Sopariwala D, Bal N, Bruhn D, Kopec W . The N Terminus of Sarcolipin Plays an Important Role in Uncoupling Sarco-endoplasmic Reticulum Ca2+-ATPase (SERCA) ATP Hydrolysis from Ca2+ Transport. J Biol Chem. 2015; 290(22):14057-67. PMC: 4447977. DOI: 10.1074/jbc.M115.636738. View

11.

Wang Y, Zhou D, Phung S, Masri S, Smith D, Chen S . SGK3 is an estrogen-inducible kinase promoting estrogen-mediated survival of breast cancer cells. Mol Endocrinol. 2010; 25(1):72-82. PMC: 3089033. DOI: 10.1210/me.2010-0294. View

12.

Wang Y, Zhou D, Chen S . SGK3 is an androgen-inducible kinase promoting prostate cancer cell proliferation through activation of p70 S6 kinase and up-regulation of cyclin D1. Mol Endocrinol. 2014; 28(6):935-48. PMC: 4042072. DOI: 10.1210/me.2013-1339. View

13.

Shapiro D, Livezey M, Yu L, Zheng X, Andruska N . Anticipatory UPR Activation: A Protective Pathway and Target in Cancer. Trends Endocrinol Metab. 2016; 27(10):731-741. PMC: 5035594. DOI: 10.1016/j.tem.2016.06.002. View

14.

Thor D, Uchizono J, Lin-Cereghino G, Rahimian R . The effect of 17 beta-estradiol on intracellular calcium homeostasis in human endothelial cells. Eur J Pharmacol. 2010; 630(1-3):92-9. PMC: 2822064. DOI: 10.1016/j.ejphar.2009.12.030. View

15.

Murray J, Campbell D, Morrice N, Auld G, Shpiro N, Marquez R . Exploitation of KESTREL to identify NDRG family members as physiological substrates for SGK1 and GSK3. Biochem J. 2004; 384(Pt 3):477-88. PMC: 1134133. DOI: 10.1042/BJ20041057. View

16.

Hanamura T, Niwa T, Nishikawa S, Konno H, Gohno T, Tazawa C . Androgen metabolite-dependent growth of hormone receptor-positive breast cancer as a possible aromatase inhibitor-resistance mechanism. Breast Cancer Res Treat. 2013; 139(3):731-40. DOI: 10.1007/s10549-013-2595-x. View

17.

Sherk A, Frigo D, Schnackenberg C, Bray J, Laping N, Trizna W . Development of a small-molecule serum- and glucocorticoid-regulated kinase-1 antagonist and its evaluation as a prostate cancer therapeutic. Cancer Res. 2008; 68(18):7475-83. PMC: 2562281. DOI: 10.1158/0008-5472.CAN-08-1047. View

18.

Franken N, Rodermond H, Stap J, Haveman J, van Bree C . Clonogenic assay of cells in vitro. Nat Protoc. 2007; 1(5):2315-9. DOI: 10.1038/nprot.2006.339. View

19.

Clark A, West K, Streicher S, Dennis P . Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther. 2002; 1(9):707-17. View

20.

Vasudevan K, Barbie D, Davies M, Rabinovsky R, McNear C, Kim J . AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell. 2009; 16(1):21-32. PMC: 2752826. DOI: 10.1016/j.ccr.2009.04.012. View